COL5A2蛋白表达与胃癌患者临床病理指标和预后的关系

doi:10.3969/j.issn.1004-616x.2025.03.011

癌变·畸变·突变 ›› 2025, Vol. 37 ›› Issue (3): 242-247.doi: 10.3969/j.issn.1004-616x.2025.03.011

• 肿瘤防治 • 上一篇

COL5A2蛋白表达与胃癌患者临床病理指标和预后的关系

侯慧云¹, 白飞虎², 闫曦¹, 武李红¹, 左鹏玺¹, 王钧¹

1. 空军军医大学西京医院第九八六医院消化科, 陕西西安 710054;
2. 海南医科大学第二附属医院消化内科, 海南海口 570100

收稿日期:2024-04-08 修回日期:2024-10-12 发布日期:2025-06-13
通讯作者: 王钧
作者简介:侯慧云，E-mail：houhuiyun1234@163.com。
基金资助:
国家自然科学基金地区科学基金(81760440)

Correlations between COL5A2 protein expression and clinicopathological parameters in patients with gastric cancer

HOU Huiyun¹, BAI Feihu², YAN Xi¹, WU Lihong¹, ZUO Pengxi¹, WANG Jun¹

1. Department of Gastroenterology, Xijing 986 Hospital, Air Force Medical University, Xi'an 710054, Shaanxi;
2. Department of Gastroenterology, The Second Affiliated Hospital of Hainan Medical University, Haikou 570100, Hainan, China

Received:2024-04-08 Revised:2024-10-12 Published:2025-06-13

摘要/Abstract

摘要： 目的：探讨V型胶原α2(COL5A2)蛋白表达与胃癌患者临床病理指标和预后的关系。方法：收集胃癌患者的术后组织标本146例，取肿瘤和癌旁组织进行免疫组织化学染色，检测COL5A2蛋白的表达，分析其与患者临床病理指标和预后的关系。分别使用携带短发夹RNA(shRNA)和COL5A2基因载体的慢病毒感染胃癌细胞系(MKN-45和AGS)，获得稳定敲低和稳定过表达COL5A2的胃癌细胞株，并观察MKN-45和AGS胃癌细胞的增殖能力变化。结果：COL5A2蛋白在胃癌患者肿瘤组织中的阳性表达率约为39.7%，较癌旁组织升高。COL5A2 阳性组胃癌患者中 T3~T4 期比例(58.6%)、N1~N3 期比例(63.8%)、III 期比例(56.9%)均高于COL5A2阴性组(分别为36.4%、36.4%、29.5%，均为P<0.05)。生存分析显示，COL5A2阳性组胃癌患者无复发生存率和总体生存率均低于COL5A2阴性的胃癌患者(P<0.05)。过表达COL5A2的胃癌细胞系，细胞增殖显著增强；而敲低COL5A2显著抑制胃癌细胞增殖。结论：COL5A2在胃癌患者肿瘤组织中高表达，且提示更晚的TNM分期和更差的预后，过表达COL5A2可促进胃癌细胞增殖，COL5A2有望成为胃癌患者预后预测的新型生物标志物。

关键词: 胃癌, V型胶原α2, 临床预后, 临床病理指标, 细胞增殖

Abstract: OBJECTIVE： To analyze correlations between COL5A2 expression and clinical pathological characteristics of gastric cancer patients. METHODS： Among gastric cancer patients，146 of them with radical surgery were recruited. Their tumor and adjacent tissues were taken for immunohistochemical staining to detect the expression of COL5A2 protein and analyze its relationship with clinical pathological indicators，including prognosis of patients. Gastric cancer cell lines (MKN-45 and AGS) were infected with lentivirus carrying shRNA (short hairpin RNA) vector and COL5A2 gene vector to obtain gastric cancer cell strains with stable knockdown and overexpression of COL5A2， respectively. The effect of knocking down and overexpressing COL5A2 on the proliferation of MKN-45 and AGS gastric cancer cells was observed. RESULTS： The positive expression rate of COL5A2 protein in tumor tissues was 39.7% ， which was higher than that in adjacent tissues. The proportions of T3-T4 stage (58.6%)，N1-N3 stage (63.8%)，and stage III (56.9%) in the COL5A2- positive tumor tissues were higher than that in the COL5A2-negative tissues (36.4% ， 36.4% and 29.5% ， respectively，all P<0.05). Survival analysis showed that the recurrence-free survival rate and overall survival rate of patients in the COL5A2-positive group were lower than those in the COL5A2-negative group (P<0.05). Gastric cancer cell lines overexpressing COL5A2 showed significantly enhanced cell proliferation. Knocking down COL5A2 significantly inhibited the proliferation of gastric cancer cells. CONCLUSION： COL5A2 was highly expressed in tumor tissues of gastric cancer patients，indicating later TNM staging and poorer patient prognosis. Overexpression of COL5A2 promoted gastric cancer cell proliferation in vitro. COL5A2 may be useful as a new biomarker for predicting the prognosis of gastric cancer patients.

Key words: gastric cancer, COL5A2, clinical prognosis, clinical pathological characteristics, cell proliferation

中图分类号:

R735.2

侯慧云, 白飞虎, 闫曦, 武李红, 左鹏玺, 王钧. COL5A2蛋白表达与胃癌患者临床病理指标和预后的关系[J]. 癌变·畸变·突变, 2025, 37(3): 242-247.

HOU Huiyun, BAI Feihu, YAN Xi, WU Lihong, ZUO Pengxi, WANG Jun. Correlations between COL5A2 protein expression and clinicopathological parameters in patients with gastric cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 242-247.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 许浩, 胡碧川, 邹伟, 等. 行根治术的Ⅲ期胃癌患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(1): 30-36.
[3] JOHNSTON F M, BECKMAN M. Updates on management of gastric cancer[J]. Curr Oncol Rep, 2019, 21(8): 67.
[4] 杨婵君, 陈雯恬, 刘静. 胶原蛋白作为胃癌潜在生物标志物的生物信息学分析[J]. 癌变·畸变·突变, 2021, 33(6): 410- 419.
[5] MENG X Y, SHI M J, ZENG Z H, et al. The role of COL5A2 in patients with muscle-invasive bladder cancer: a bioinformatics analysis of public datasets involving 787 subjects and 29 cell lines[J]. Front Oncol, 2018, 8: 659.
[6] WANG J, JIANG Y H, YANG P Y, et al. Increased collagen type V α2(COL5A2) in colorectal cancer is associated with poor prognosis and tumor progression[J]. Onco Targets Ther, 2021, 14: 2991-3002.
[7] 朱虹蓂. COL5A2在卵巢肿瘤微环境中的表达变化及其对卵巢癌促进作用的机制[D]. 长春: 吉林大学, 2022.
[8] NISSEN N I, KARSDAL M, WILLUMSEN N. Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology[J]. J Exp Clin Cancer Res, 2019, 38(1): 115.
[9] TAN Y E, CHEN Q C, XING Y, et al. High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer[J]. Biosci Rep, 2021, 41(4): BSR20204293.
[10] DING Y L, SUN S F, ZHAO G L. COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis[J]. Medicine, 2021, 100(7): e24561.
[11] MAO D L, XU R, CHEN H X, et al. Cross-talk of focal adhesion-related gene defines prognosis and the immune microenvironment in gastric cancer[J]. Front Cell Dev Biol, 2021, 9: 716461.
[12] CAO L, CHEN Y, ZHANG M, et al. Identification of hub genes and potential molecular mechanisms in gastric cancer by integrated bioinformatics analysis[J]. PeerJ, 2018, 6: e5180.
[13] RUSSI S, VERMA H K, LAURINO S, et al. Adapting and surviving: intra and extra-cellular remodeling in drug-resistant gastric cancer cells[J]. Int J Mol Sci, 2019, 20(15): 3736.
[14] HSIEH C H, TAI S K, YANG M H. Snail-overexpressing cancer cells promote M2-like polarization of tumor-associated macrophages by delivering miR-21-abundant exosomes[J]. Neoplasia, 2018, 20(8): 775-788.
[15] ANDRIKOPOULOS K, LIU X, KEENE D R, et al. Targeted mutation in the col5a2 gene reveals a regulatory role for type V collagen during matrix assembly[J]. Nat Genet, 1995, 9(1): 31- 36.
[16] YIN W, ZHU H C, TAN J, et al. Identification of collagen genes related to immune infiltration and epithelial-mesenchymal transition in glioma[J]. Cancer Cell Int, 2021, 21(1): 276.
[17] DENARDO D G, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19(6): 369-382.
[18] WORKMAN C J, SZYMCZAK-WORKMAN A L, COLLISON L W, et al. The development and function of regulatory T cells [J]. Cell Mol Life Sci, 2009, 66(16): 2603-2622.

COL5A2蛋白表达与胃癌患者临床病理指标和预后的关系

Correlations between COL5A2 protein expression and clinicopathological parameters in patients with gastric cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭婧, 谢观超, 王意浓, 蔡岩, 张钰, 王明荣, 郝佳洁. 食管鳞癌中STMN3高表达及其促癌作用机制[J]. 癌变·畸变·突变, 2025, 37(2): 89-95,104.
[2]	吴秀浅, 梁泰榕, 庄学龙, 王星星, 黄海花. DKK-1和NNMT与肝癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2024, 36(6): 452-456,462.
[3]	邸荣炜, 付鑫雅, 马秀梅, 李超, 海玲. CDK4/6抑制剂阿贝西利联合顺铂对人胃癌细胞生物学行为的影响[J]. 癌变·畸变·突变, 2024, 36(5): 384-390.
[4]	朱文标, 闫春梅, 丘波, 谢寿城, 肖焕钦, 刘高敏. 分泌型卷曲相关蛋白4在肝细胞癌中的表达及其与患者临床病理指标和预后的关系[J]. 癌变·畸变·突变, 2024, 36(4): 288-293,297.
[5]	孙鑫, 李爽, 陆雪, 蔡恬静, 刘雅, 刘青杰, 张伟. 低剂量电离辐射对人淋巴细胞氧化应激及DNA损伤的影响[J]. 癌变·畸变·突变, 2024, 36(2): 94-99.
[6]	王馨焱, 刘晓玲, 贾军梅. 淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展[J]. 癌变·畸变·突变, 2024, 36(1): 80-83.
[7]	郑雅琪, 赵子婷, 潘德渊, 刘禄鑫, 许秀娥, 廖连娣, 王少洪, 李恩民, 许丽艳. TONSL在食管癌中的表达及其影响食管鳞癌细胞增殖的机制[J]. 癌变·畸变·突变, 2023, 35(6): 412-419.
[8]	何广思, 魏洁, 张健. 血清miRNA-183与CA199联合检测在胃癌诊断和预后评估中的价值[J]. 癌变·畸变·突变, 2023, 35(6): 457-461,466.
[9]	高榴, 禹莉. 线粒体转录因子A在肿瘤发生发展中作用的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 485-488.
[10]	冯丹, 范志露, 王意浓, 李赛, 郭婧, 蔡岩, 张钰, 魏文强, 王明荣, 郝佳洁. P4HA2通过激活EGFR/AKT/S6信号通路促进食管鳞癌细胞的增殖[J]. 癌变·畸变·突变, 2023, 35(2): 87-94,101.
[11]	秦景娜, 周英发, 刘贺勇. 炎症指标和肿瘤标记物联合检测对术前胃癌分期的诊断价值[J]. 癌变·畸变·突变, 2023, 35(2): 139-143.
[12]	许浩, 胡碧川, 邹伟, 段雅斌. 行根治术的Ⅲ期胃癌患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(1): 30-36.
[13]	张军军, 梁乐平. PTEN C末端对鼻咽癌细胞迁移及增殖能力的影响[J]. 癌变·畸变·突变, 2022, 34(6): 434-438.
[14]	毕佳欣, 王晓雪, 赵若晗, 韩旭, 宋洁. 着丝粒蛋白T在乳腺癌中表达及其启动子区变异的研究[J]. 癌变·畸变·突变, 2022, 34(5): 327-334.
[15]	张晓帆, 钟旋, 罗杰鹏, 欧阳斌发, 李博, 李华文, 彭晓琳. 深圳市南山区2011—2019年胃癌发病特征及趋势[J]. 癌变·畸变·突变, 2022, 34(4): 269-272,278.